Combination therapy with anti-PD-1, anti-TIM-3, and focal radiation results in regression of murine gliomas

JE Kim, MA Patel, A Mangraviti, ES Kim… - Clinical Cancer …, 2017 - AACR
Purpose: Checkpoint molecules like programmed death-1 (PD-1) and T-cell immunoglobulin
mucin-3 (TIM-3) are negative immune regulators that may be upregulated in the setting of …

Patient characteristics associated with choosing a telemedicine visit vs office visit with the same primary care clinicians

…, I Graetz, C Lee, E Muelly, C Kennedy, E Kim - JAMA network …, 2020 - jamanetwork.com
Importance Video or telephone telemedicine can offer patients access to a clinician without
arranging for transportation or spending time in a waiting room, but little is known about …

TIGIT and PD-1 dual checkpoint blockade enhances antitumor immunity and survival in GBM

…, Z Belcaid, D Mathios, AS Luksik, E Kim… - …, 2018 - Taylor & Francis
The use of inhibitory checkpoint blockade in the management of glioblastoma has been
studied in both preclinical and clinical settings. TIGIT is a novel checkpoint inhibitor recently …

Anti–PD-1 antitumor immunity is enhanced by local and abrogated by systemic chemotherapy in GBM

D Mathios, JE Kim, A Mangraviti, J Phallen… - Science translational …, 2016 - science.org
The immunosuppressive effects of chemotherapy present a challenge for designing effective
cancer immunotherapy strategies. We hypothesized that although systemic chemotherapy (…

Lhx6-positive GABA-releasing neurons of the zona incerta promote sleep

K Liu, J Kim, DW Kim, YS Zhang, H Bao, M Denaxa… - Nature, 2017 - nature.com
Multiple populations of wake-promoting neurons have been characterized in mammals, but
few sleep-promoting neurons have been identified 1 . Wake-promoting cell types include …

Management of frailty: a systematic review and network meta-analysis of randomized controlled trials

…, J Alzahrani, M Maaz, MM Ahmed, E Kim… - Journal of the American …, 2019 - Elsevier
Objective To analyze and determine the comparative effectiveness of interventions targeting
frailty prevention or treatment on frailty as a primary outcome and quality of life, cognition, …

Expression of LAG‐3 and efficacy of combination treatment with anti‐LAG‐3 and anti‐PD‐1 monoclonal antibodies in glioblastoma

…, D Mathios, AM Martin, Y Xia, E Kim… - … journal of cancer, 2018 - Wiley Online Library
Like in many tumor types, immunotherapy is currently under investigation to assess its
potential efficacy in glioblastoma patients. Trials are under way to assess the efficacy of new …

Combination anti-CXCR4 and anti-PD-1 immunotherapy provides survival benefit in glioblastoma through immune cell modulation of tumor microenvironment

…, Y Xia, P Cardarelli, M Oyasu, Z Belcaid, E Kim… - Journal of neuro …, 2019 - Springer
Background Emerging evidence suggests that myeloid cells play a critical role in glioblastoma
(GBM) immunosuppression. Disappointing results of recent checkpoint inhibitor trials …

Contrasting impact of corticosteroids on anti-PD-1 immunotherapy efficacy for tumor histologies located within or outside the central nervous system

…, AS Luksik, T Garzon-Muvdi, AL Hung, ES Kim… - …, 2018 - Taylor & Francis
Immune checkpoint blockade targeting programmed cell death protein 1 (PD-1) is emerging
as an important treatment strategy in a growing list of cancers, yet its clinical benefits are …

[HTML][HTML] Dendritic cell activation enhances anti-PD-1 mediated immunotherapy against glioblastoma

…, D Theodros, AS Luksik, R Maxwell, E Kim… - Oncotarget, 2018 - ncbi.nlm.nih.gov
Results We show that activating DCs through TLR3 agonists enhances the anti-tumor immune
response to CB and increases survival in GBM. Mice treated with TLR3 agonist poly (I: C) …